Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results

被引:382
作者
Rustin, GJS [1 ]
Galbraith, SM
Anderson, H
Stratford, M
Folkes, LK
Sena, L
Gumbrell, L
Price, PM
机构
[1] Mt Vernon Hosp, Dept Med Oncol, Northwood HA6 2RN, Middx, England
[2] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England
[3] Hammersmith Hosp, Canc Res United Kingdom Positron Emiss Tomog Onco, London, England
[4] Canc Res United Kingdom, London, England
关键词
D O I
10.1200/JCO.2003.05.185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. Patients and Methods: The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose escalation. Dose escalation was accomplished by doubling until grade 2 toxicity was seen. The starting dose was 5 mg/m(2). Results: Thirty-four patients received 167 infusions. CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide. CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m(2) to 3.29 mumol . h/L at 114 mg/m(2). The mean CA4 AUC in eight patients at 68 mg/m(2) was 2.33 mumol . h/L compared with 5.8 mumol . h/L at 25 mg/kg (the lowest effective dose) in the mouse. The only toxicity that possibly was related to the drug dose up to 40 mg/m(2) was tumor pain. Dose-limiting toxicity was reversible ataxia at 114 mg/m(2), vasovagal syncope and motor neuropathy at 88 mg/m(2), and fatal ischemia in previously irradiated bowel at 52 mg/m(2). Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea. One patient at 68 mg/m(2) had improvement in liver metastases of adrenocortical carcinoma. Conclusion: CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m(2); these are doses at which tumor blood flow reduction has been recorded.
引用
收藏
页码:2815 / 2822
页数:8
相关论文
共 26 条
[1]   Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].
Anderson, HL ;
Yap, JT ;
Miller, MP ;
Robbins, A ;
Jones, T ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830
[2]  
Bloemendal HJ, 1999, EUR J CLIN INVEST, V29, P802
[3]  
Chaplin DJ, 1996, BRIT J CANCER, V74, pS86
[4]  
Chaplin DJ, 1999, ANTICANCER RES, V19, P189
[5]  
Dark GG, 1997, CANCER RES, V57, P1829
[6]   THE CURRENT STATUS OF TARGETING TUMOR VASCULATURE AS A MEANS OF CANCER-THERAPY - AN OVERVIEW [J].
DENEKAMP, J .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1991, 60 (1-2) :401-408
[7]   ENDOTHELIAL CELL-PROLIFERATION AS A NOVEL-APPROACH TO TARGETING TUMOR-THERAPY [J].
DENEKAMP, J .
BRITISH JOURNAL OF CANCER, 1982, 45 (01) :136-139
[8]  
Dowlati A, 2002, CANCER RES, V62, P3408
[9]  
Galbraith SM, 2001, ANTICANCER RES, V21, P93
[10]   Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging [J].
Galbraith, SM ;
Maxwell, RJ ;
Lodge, MA ;
Tozer, GM ;
Wilson, J ;
Taylor, NJ ;
Stirling, JJ ;
Sena, L ;
Padhani, AR ;
Rustin, GJS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2831-2842